Precision BioSciences Inc. has announced that it will deliver a late-breaking oral presentation at the Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases. The presentation will cover new data from the first two cohorts of the Phase 1 ELIMINATE-B Trial evaluating PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B. The abstract, titled "PBGENE-HBV, a First-in-class Gene Editing Therapy for Chronic Hepatitis B, Demonstrates Safety and Antiviral Activity in Early Cohorts," will be presented on November 10, 2025. The results from this study have not yet been presented and will be shared at the upcoming meeting in Washington, D.C.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014340177) on October 14, 2025, and is solely responsible for the information contained therein.